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Abstract
Introduction: Critical illness is characterized by oxidative stress, which is a major promoter of systemic
inflammation and organ failure due to excessive free radical production, depletion of antioxidant defenses, or both.
We hypothesized that exogenous supplementation of trace elements and vitamins could restore antioxidant status,
improving clinical outcomes.
Methods: We searched computerized databases, reference lists of pertinent articles and personal files from 1980 to
2011. We included randomized controlled trials (RCTs) conducted in critically ill adult patients that evaluated
relevant clinical outcomes with antioxidant micronutrients (vitamins and trace elements) supplementation versus
placebo.
Results: A total of 21 RCTs met inclusion criteria. When the results of these studies were statistically aggregated (n
= 20), combined antioxidants were associated with a significant reduction in mortality (risk ratio (RR) = 0.82, 95%
confidence interval (CI) 0.72 to 0.93, P = 0.002); a significant reduction in duration of mechanical ventilation
(weighed mean difference in days = -0.67, 95% CI -1.22 to -0.13, P = 0.02); a trend towards a reduction in
infections (RR= 0.88, 95% CI 0.76 to 1.02, P = 0.08); and no overall effect on ICU or hospital length of stay (LOS).
Furthermore, antioxidants were associated with a significant reduction in overall mortality among patients with
higher risk of death (>10% mortality in control group) (RR 0.79, 95% CI 0.68 to 0.92, P = 0.003) whereas there was
no significant effect observed for trials of patients with a lower mortality in the control group (RR = 1.14, 95% 0.72
to 1.82, P = 0.57). Trials using more than 500 μg per day of selenium showed a trend towards a lower mortality (RR
= 0.80, 95% CI 0.63 to 1.02, P = 0.07) whereas trials using doses lower than 500 μg had no effect on mortality (RR
0.94, 95% CI 0.67 to 1.33, P = 0.75).
Conclusions: Supplementation with high dose trace elements and vitamins may improve outcomes of critically ill
patients, particularly those at high risk of death.
Introduction
Critical illness is characterized by hyperinflammation,
cellular immune dysfunction, oxidative stress and mito-
chondrial dysfunction [1]. Oxidative stress is defined as
a state in which the level of toxic reactive oxygen inter-
mediates overcome the endogenous antioxidant defenses
of the host and damage biologically relevant molecules,
such as DNA, RNA, proteins, carbohydrates and unsatu-
rated fatty acids of the cell membranes [2-5]. Oxidative
stress may not be considered an epiphenomenon in the
critically ill patient but part of the underlying
pathophysiologic events leading to mitochondrial dys-
function and the systemic inflammatory response syn-
drome (SIRS), which can lead to multiple organ
dysfunction syndrome (MODS) [6].
The antioxidant endogenous defense system in
humans consists of a variety of extracellular and intra-
cellular antioxidants which are able to protect tissues
from reactive oxygen species (ROS) and reactive nitro-
gen species (RNS) induced injury [3]. Trace elements,
such as copper, manganese, zinc, iron and selenium are
required for the activity of superoxide dismutase (SOD),
catalase and glutathione peroxidase (GPx), respectively.
In addition, the non-enzymatic defense mechanisms
include endogenous molecules (that is, glutathione,
albumin) and vitamins (such as E, C and b-carotene)
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[2,3]. Low levels of endogenous vitamins and trace ele-
ments in SIRS are due to escape to the interstitial com-
partment by capillary leakage, hemodilution, previous
insufficient intake, and continuous renal replacement
therapies (CRRT) [7]. In the critically ill, the most severe
cases of SIRS are associated with the most severe anti-
oxidant depletion [8-10].
In the last two decades, several clinical trials have
evaluated the role of antioxidant micronutrients as
monotherapy or in combined therapy (enteral or parent-
eral antioxidant cocktails) as part of an antioxidant
strategy for critically ill SIRS patients. These have been
reviewed in prior meta-analyses but since these publica-
tions [11,12], additional RCTs have been reported
[13-18]. The aim of the current study was to provide an
up-to-date systematic review and meta-analysis on all
randomized clinical studies of vitamins and trace ele-
ments as pharmaconutrient therapy on relevant clinical
outcomes in critically ill patients. In addition, we con-
ducted several hypothesis-generating subgroup analyses




We conducted a systematic review of the published lit-
erature to identify all relevant clinical trials using text
word or MeSH headings containing “randomized,”
“blind,” “clinical trial,” “nutritional support”, “enteral
nutrition”, “parenteral nutrition”, antioxidants,” “vita-
mins”, “trace elements”, “selenium”, “zinc”, “copper”,
“manganese”, “vitamins A, C and E”, “critical illness”
and “critically ill”. To locate these articles we performed
computerized searches on MEDLINE, EMBASE,
CINAHL the Cochrane Controlled Trials Register, and
the Cochrane Database of Systematic Reviews) from
1980 to December 2011. We also searched our personal
files and comprehensive review articles were searched
for additional original studies. No language restrictions
were placed on the searches. Abstracts from scientific
meetings were accepted for inclusion into this systema-
tic review if a copy of the manuscript was available to
complete the abstraction form.
Study selection criteria
We only included original studies if they met the follow-
ing inclusion criteria: a) study design: randomized clini-
cal trials (RCTs); b) population: critically ill adult
patients (>18 years of age); c) intervention: trace ele-
ments and/or vitamins versus placebo (either via enteral,
parenteral, or both); d) study outcomes: must have
included one of the following: mortality, intensive care
unit (ICU) and hospital length of stay (LOS), infectious
complications, and other clinically important
complications. We excluded the clinical studies that
reported only biochemical, metabolic, immunologic or
nutritional outcomes. We have excluded trials that sup-
plemented N-acetylcysteine (NAC) [19,20] in addition to
trace elements and vitamins because this amino acid has
shown to be potentially harmful in critically ill SIRS
patients, particularly when it is started 24 hours after
hospital admission [21].
Additionally, we excluded clinical studies that supple-
mented selected substrates, such as glutamine, arginine
and omega-3 fatty acids, as pharmaconutrients in
immune-enhancing diets (IEDs) in addition to vitamins
and trace elements. Critically ill patients were defined as
patients admitted to an ICU. When this was unclear, we
considered a mortality rate higher than 5% in the con-
trol group to be consistent with critical illness.
All original studies were abstracted in duplicate inde-
pendently by two reviewers, using a data abstraction
form with a scoring system (Additional file 1 Table s1),
which has been used previously [22]. Disagreement in
the individual scores of each of the categories was
resolved by consensus between both reviewers. We
attempted to contact the authors of included studies
and requested additional information not contained in
published articles. We scored the methodological quality
of individual trials considering the following key features
of high-quality studies: a) extent to which randomization
was concealed, b) blinding, c) analysis was based on the
intention-to-treat (ITT) principle, d) comparability of
groups at baseline, e) extent of follow-up, f) description
of treatment protocol and co-interventions, and g) defi-
nition of clinical outcomes. Each individual study was
scored from 0 to 14 (Table 1).
Data synthesis
The primary outcome of the systematic review was
overall mortality. From all studies, we combined hospital
mortality where reported (specified or assumed to be
hospital if not specified). If hospital mortality was not
reported, we used ICU mortality or, if ICU mortality
was not reported, we used 28-day mortality. Secondary
outcomes included infection and ICU and hospital LOS.
We used definitions of infections as defined by the
authors in their original papers. If studies had more
than one experimental intervention, these were each
considered separately. We combined data from all trials
to estimate the pooled risk ratio (RR) with 95% confi-
dence intervals for death and infectious complications
and overall weighted mean difference (WMD) with 95%
confidence intervals for LOS data. All analyses, except
the test for asymmetry, were conducted using Review
Manager (RevMan) 5.1 software. (The Nordic Cochrane
Centre, The Cochrane Collaboration, Copenhagen, Den-
mark, 2011) [23]. Pooled RRs were calculated using the
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Mantel-Haenszel estimator and WMDs were estimated
by the inverse variance approach. The random effects
model of DerSimonian and Laird was used to estimate
variances for the Mantel-Haenszel and inverse variance
estimators [24]. RRs are undefined and excluded for stu-
dies with no event in either arm. When possible, studies
were aggregated on an intention-to-treat basis (Table 2).
The presence of heterogeneity was tested by a weighted
Mantel-Haenszel chi-square test and quantified by the
I2 statistic as implemented in RevMan 5.1 [25]. The
possibility of publication bias was assessed by generating
funnel plots and testing asymmetry of outcomes using
methods proposed by Rucker and colleagues [26]. We
considered P <0.05 to be statistically significant and P
<0.20 as the indicator of trend.
A priori hypotheses testing
Given the larger number of trials and the heterogeneity
of trial design, we performed several pre-specified,
hypothesis-generating subgroup analysis to attempt to
elucidate potentially more beneficial treatment strate-
gies. Initially, we compared the results of trials that pro-
vided antioxidants via the enteral route compared to
trials that provided intravenous antioxidants. Studies
that have supplemented antioxidants using both routes
(enteral and parenteral) were excluded from the sub-
group analyses of parenteral versus enteral administra-
tion. Given that some trials showed that antioxidants,
and particularly selenium, may offer some advantage in
the most seriously ill patients, we compared studies of
patients with higher mortality in the control group vs.
lower mortality. When we considered the distribution of
control group mortality rates, there was a clustering of
studies with a mortality <10% and then a clustering with
a control groups mortality >23%. These clusters were
used in our subgroup analysis. According to the pre-
vious meta-analysis [11], selenium was considered the
cornerstone of antioxidant therapy and we compared
trials that utilized selenium in their antioxidant strategy
versus those that did not. Of those trials that utilized
selenium, we compared those that administered the
selenium via the parenteral route compared to the ent-
eral route. Of those trials that utilized intravenous sele-
nium, we considered the following additional
exploratory subgroup analyses: a) trials that use sele-
nium (monotherapy) by itself versus combined with
other nutrient (combination therapy); b) trials that uti-
lized an intravenous rapid bolus loading dose of sele-
nium versus those that did not; c) trials that provided
parenteral selenium via continuous infusion versus par-
enteral selenium via intermittent bolus; and finally d)
studies that utilized a selenium daily dose lower than
500 μg, equal to 500 μg, and greater than 500 μg.
Results
Study identification and selection
A total of 55 relevant citations were identified from the
search of computerized bibliographic databases and a
review of reference lists from related articles. Of these,
we excluded 34 due to the following reasons: 14 trials
did not include ICU patients [27-40]; 4 trials did not
evaluate clinically important outcomes [41-44]; 7 trials
studied nutrients other than micronutrients (vitamins
and trace elements) [19,20,45-49]; 3 trials were dupli-
cated publications of included trials [50-52]; 2 were
meta-analysis or systematic reviews [15,53]; and 3 addi-
tional trials were excluded because one was published
only as an abstract without possibility to access the full
article [54] and one was pseudorandomized [55]. In the
end, 21 RCTs including 2,531 patients met the inclusion
criteria and were included in this systematic review
[13-18,56-70] (Additional file 2, Table s2; Additional file
3, Table s3). The authors reached 100% agreement for
inclusion of relevant trials in this review. The mean
methodological score of all trials was 8.3 (range 4 to 13)
of a maximum of 14. Randomization was concealed in
5/20 (24%) trials, ITT analysis was performed in 12/20
(60%) trials and 8/20 (40%) trials were double blinded.
Meta-analyses of primary outcome
Overall effect on mortality
When the results of 20 RCTs [13-18,56-70] that evalu-
ated mortality as one of the outcomes were statistically
aggregated, overall antioxidant micronutrients were
associated with a significant reduction in mortality (risk
ratio (RR) = 0.82, 95% confidence intervals (CI) 0.72 to
0.93, P = 0.002; see Figure 1). The test for heterogeneity
was not significant (P = 0.42, I2 = 3.0%). A funnel plot
(data not shown) was created and the test of asymmetry
was not significant (P = 0.35).
Secondary outcomes
Overall effect on infectious complications
Ten trials [13,14,16,17,57,62-65,67] reported overall
infections and when these data were aggregated, antioxi-
dant strategies were associated with a trend towards a
reduction in infectious complications in critically ill
patients (RR= 0.88, 95% CI 0.76 to 1.02, P = 0.08, see
Figure 2). The test for heterogeneity was not significant
(P = 0.52, I2 = 0%).
Overall effect on length of stay
When the nine trials [13,16,18,60,62,64,67,68,70] that
reported on ICU LOS were aggregated, antioxidants had
no effect in LOS WMD = 0.07, 95% CI -0.08, 0.22, P =
0.38). Furthermore, there was no effect on hospital LOS
when the data from five trials [13,16,60,62,64] reporting
on this outcome were aggregated (WMD = -0.13, 95%
Manzanares et al. Critical Care 2012, 16:R66
http://ccforum.com/content/16/2/R66
Page 3 of 13
CI -0.35 to 0.09, P = 0.25; test for heterogeneity was not
significant P = 0.73, I2 = 0%).
Overall effect on ventilator days
When the four trials [14,60,64,66] that reported ventila-
tor days were aggregated, antioxidants significantly
decreased the duration of mechanical ventilation (WMD
= -0.67, 95% CI -1.22 to -0.13, P = 0.02, see Figure 3).
Subgroup analysis
Parenteral/Intravenous versus enteral route
Antioxidants were supplemented by parenteral route in 15
[13-17,57,59-62,64,67-70] of the 21 trials; 1 trial [65] was
excluded because it supplemented vitamin E by enteral
route and vitamin C by parenteral route. When the results
of the trials using antioxidants via parenteral route were
Figure 1 Effects of antioxidant strategies on mortality (n = 20). AOX, antioxidants; RR, risk ratio; 95% CI, 95% confidence intervals.
Figure 2 Effect of antioxidants on infections (n = 10). AOX, antioxidants; RR, risk ratio; 95% CI, 95% confidence intervals.
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aggregated, antioxidants were associated with a trend
towards reduction in mortality (RR = 0.89, 95% CI 0.77 to
1.03, P = 0.11); test for heterogeneity was not significant P
= 0.56, I2 = 0%). Meanwhile, four trials [18,63,65,66] that
evaluated antioxidants by enteral route were associated
with a significant reduction in mortality (RR = 0.68, 95%
CI 0.54 to 0.85, P = 0.0008; test for heterogeneity P = 0.50,
I2 = 0%, see Figure 4). The test for subgroup differences
was borderline significant, P = 0.05, I2 = 0%. Seven trials
[13,14,17,57,62,64,67] using intravenous antioxidants eval-
uated infectious complications. When aggregated these
studies showed that antioxidant supplementation by intra-
venous route was associated with a trend towards reduced
infections (RR = 0.89, 95% CI 0.76 to 1.03, P = 0.12; test
for heterogeneity was not significant P = 0.57, I2 = 0%).
Only one RCT [63] reported the effects of enteral antioxi-
dants on infections, so meta-analysis was not done.
Higher vs. lower mortality
Subgroup analyses showed that antioxidant supplemen-
tation was associated with a significant reduction in
overall mortality among patients with higher risk of
death [15-18,56,58,59,61,66,67,69,70] (>10% mortality in
the control group) (RR 0.79, 95% CI 0.68 to 0.92, P =
0.003). There was no significant effect observed for the
trials of patients with a lower mortality in the control
group [13,14,60,62-65,68] (RR = 1.14, 95% CI 0.72 to
1.82, P = 0.57). The test for subgroup differences was
not significant (P = 0.14, I2 = 54%, see Figure 5). Six
trials with low mortality in the control group
[13,14,62-65] showed no effect on infections (RR = 0.87,
95% CI 0.69 to 1.10, P = 0.25). Furthermore, four trials
with higher mortality in the control group [16,17,57,67]
did not show effect on infections (RR = 0.95, 95% CI
0.60 to 1.49, P = 0.81). The test for subgroup differences
was not significant (P = 0.76).
Selenium versus non-selenium
There were 16 trials [13-18,56,59-62,65,67-70] that eval-
uated selenium alone or combined with other micronu-
trients in antioxidant cocktails. When aggregated,
selenium supplementation was associated with a trend
toward a reduction in mortality (RR = 0.89, 95% CI 0.77
to 1.03, P = 0.12). When trials that did not use selenium
were aggregated [58,63,65,66], there was a significant
reduction in mortality (RR = 0.66, 95% CI 0.52 to 0.82,
P = 0.0003). The test for subgroup differences was sig-
nificant (P = 0.03). The seven trials using selenium
[13,14,16,17,62,64,67] demonstrated a trend toward a
reduction in infections (RR = 0.87, 95% CI 0.74 to 1.02,
P = 0.08) whereas three trials not using selenium
[57,63,65] had no effect on infectious complications (RR
= 1.10 95% CI 0.60 to 2.04, P = 0.75). The test for sub-
group differences was not significant (P = 0.46).
Parenteral vs. enteral selenium
Next, we compared those trials that administered the
selenium via the parenteral route versus the enteral
route. There were 15 trials that evaluated parenteral
selenium [13-18,56,59-61,64,67-70]. When aggregated,
parenteral selenium supplementation was associated
with a trend toward a reduction in mortality (RR = 0.89,
95% CI 0.77 to 1.03, P = 0.11). Furthermore, seven trials
[13,14,16,17,62,64,67] using parenteral selenium demon-
strated a trend toward a reduction in infections (RR =
0.87, 95% CI 0.74 to 1.02, P = 0.08). We could not
meta-analyze the enteral subgroup because only one
RCT [18] using enteral selenium reported on mortality,
infections, ICU and hospital LOS.
Parenteral selenium subgroup analyses
Selenium monotherapy versus selenium combined
Nine RCT [15-17,56,59,61,67,69,70] have supplemented
selenium as monotherapy. When we aggregated these
studies, selenium supplementation showed a trend
toward reduction in mortality (RR = 0.86, 95% CI 0.73
to 1.01, P = 0.06). When the effect on mortality of five
trials [13,60,62,64,68] using selenium in combined ther-
apy was evaluated, parenteral antioxidants cocktails with
selenium had no effect on mortality (RR = 1.50, 95% CI
0.77 to 2.94, P = 0.23). The test for subgroup differences
tended towards statistical significance (P = 0.11, see Fig-
ure 6).
The effect of selenium monotherapy on infections was
evaluated in three trials [16,17,67] showing a trend
towards reductions in infectious complications (RR =
0.85, 95% CI 0.71 to 1.03, P = 0.10). Meanwhile, four
RCTs [13,14,62,64] evaluated combined therapy and
Figure 3 Effect of combined antioxidant therapy on ventilation days (n = 4). RR, risk ratio; 95% CI, 95% confidence intervals.
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showed no effect on infections (RR = 0.88, 95% CI 0.66
to 1.18, P = 0.40); test for subgroup differences was not
significant (P = 0.86, see Figure 7).
Intravenous loading dose versus no loading dose Par-
enteral selenium via loading dose as a bolus was evalu-
ated in five RCTs [13,15,16,59,67]. When these studies
were aggregated, selenium supplementation with a bolus
showed a trend toward reduction in a mortality (RR =
0.81, 95% CI 0.65 to 1.02, P = 0.07; test for heterogene-
ity P = 0.40, I2 = 1%). On the other hand, parenteral
selenium without loading dose was evaluated in 10 trials
[14,17,56,60-62,64,68-70] and did not show effect on
mortality (RR = 0.95, 95% CI 0.78 to 1.15, P = 0.59).
The test of subgroup effects was not significant (P =
0.63, see Figure 6).
The effect of selenium loading dose on infections was
evaluated in three trials [13,16,67] and showed no effect
in infectious complications (RR = 0.96, 95% CI 0.69 to
1.33, P = 0.80). Meanwhile, four trials [14,17,62,64]
evaluated parenteral selenium without loading dose and
showed a borderline effect on infections (RR 0.84, 95%
CI 0.70 to 1.00, P = 0.05); test for subgroup differences
was not significant (P = 0.48, see Figure 7).
Selenium high dose versus lower dose Four trials
[16,59,67,69] using higher doses than a daily dose of 500
μg showed a trend towards a lower mortality (RR =
0.80, 95% CI 0.63 to 1.02, P = 0.07). The four trials
[15,17,56,64] using doses equal to 500 μg had a smaller
treatment effect that was not statistically significant (RR
= 0.87, 95% CI 0.57 to 1.32, P = 0.51). Meanwhile, the
seven trials [13,14,60-62,68,69] using doses lower than
500 μg had no effect on mortality (RR = 0.94, 95% CI
0.67 to 1.33, P = 0.75). Although numerically different,
these effects’ size differences are clinically important,
but the test for subgroup differences was not significant
(P = 0.75, see Figure 6).
Two trials [16,67] using doses higher than of 500 μg/d
showed no effect on infections (RR = 0.76, 95% CI 0.35
Figure 4 Effect of combined antioxidant by parenteral (n = 15) and enteral route on mortality (n = 4). AOX, antioxidants; EN: enteral
nutrition; PN: parenteral nutrition; RR, risk ratio; 95% CI, 95% confidence intervals.
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to 1.69, P = 0.51). The two trials [17,64] using doses
equal to 500 μg/d showed a trend towards a lower infec-
tions (RR = 0.86, 95% CI 0.71 to 1.05, P = 0.13) and the
three trials [13,14,62] that used doses lower than 500
μg/d had no effect on infections (RR = 0.87, 95% CI
0.64 to 1.19, P = 0.39). The test for subgroup differences
was not significant (P = 0.95, see Figure 7).
Discussion
Critical illness is associated with a significant redox
imbalance which leads to mitochondrial dysfunction,
SIRS and MODS [1,6]. In this context, it may be that
supplemental trace elements and vitamins represent an
important therapeutic option for critically ill patients.
We have systematically reviewed 21 eligible RCTs in
ICU patients for evaluating the effects of combined anti-
oxidants (vitamins and trace elements) where the nutri-
ents are provided dissociated from standard nutrition.
With the exception of six larger trials [13,15,17,65-67],
most RCTs included in this systematic review were rela-
tively small studies with the number of patients less
than 100, and thus inadequate to detect clinically impor-
tant treatment effects of combined antioxidants on mor-
tality. The advantage of meta-analytic techniques is that
they can combine across studies to gain a more precise
treatment effect. When they were statistically aggre-
gated, we found a significant reduction in mortality and
mechanical ventilation days and a trend towards
reduced infections with no overall effect on ICU or hos-
pital LOS in critically ill patients. Since the mortality
effect is greater than the effect on infectious complica-
tions, it is plausible that the mortality effect could be
mediated by different mechanisms related to improve-
ment of organ failure, not by reducing infection,
although this is only a postulate and not supported by
our data. Furthermore, given the wide variety of clinical
Figure 5 Effects of antioxidants supplementation on mortality according to high or low mortality in the control group. AOX,
antioxidants; RR, risk ratio; 95% CI, 95% confidence intervals.
Manzanares et al. Critical Care 2012, 16:R66
http://ccforum.com/content/16/2/R66
Page 7 of 13
diagnoses and the heterogenous population of ICU
patients included in this systematic review (sepsis, severe
sepsis/septic shock, trauma, burns, pancreatitis, head
injury and SIRS) the results and conclusions may be
applied to a broad, heterogeneous group of critically ill
patients.
The presence of clinical and statistical heterogeneity in
this meta-analysis enables us to explore the sources of
heterogeneity and illuminate strategies for optimizing
the treatment effect of antioxidants in critically ill
patients. Accordingly, we conducted several hypothesis-
generating analyses. We observed that enteral antioxi-
dants had a larger treatment effect on mortality (RR =
0.68 vs. 0.89). Notwithstanding, the data supporting ent-
eral antioxidants are sparse and we have not really eval-
uated all end points comprehensively. Furthermore, the
mortality effect is largely driven by the Crimi et al. [66]
trial, a large RCT (n = 216) that showed that antioxidant
supplementation with vitamins C (500 mg/d) and E (400
UI/d) in enteral feeding for 10 days is associated with
decreased 28-day mortality (45.7% versus 67.5% P <0.05)
[66]. This trial explains 83.5% of the signal and is thus a
very unstable estimate. In addition, high mortality
observed in the regular feeding group questions the gen-
eralizabily of this study. Finally, we still show a possible
treatment effect with parenteral antioxidants on infec-
tious complications. Therefore, we do not conclude that
enteral antioxidants are better but would suggest that
either route of administration is acceptable given our
current knowledge. In fact, there is a rationale for com-
bining enteral with parenteral antioxidants to maximize
the likelihood of treatment effect [71].
We have demonstrated a more pronounced effect in
reducing mortality with antioxidant strategies in the
most seriously ill ICU patients. In fact, when we aggre-
gated the data across the RCTs using a mortality cut off
value of 10% in the control group, we found a signifi-
cant effect of antioxidant supplementation in RCT with
Figure 6 Results of subgroup analyses examining the effect of parenteral selenium supplementation on mortality. RR, risk ratio. P-values
refer to the differences in the effects of selenium on mortality between subgroups.
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a mortality higher than 10% (P = 0.003). This finding
supports the notion that patients with more severe
insults and higher mitochondrial dysfunction resulting
from bioenergetic failure exhibited the largest depletion
of antioxidants [72]. Therefore, these patients may exhi-
bit greater improvement with antioxidant supplementa-
tion compared to less sick patients.
In another subgroup analysis, antioxidant strategies
without selenium were associated with a significant
reduction in mortality but no effect on infectious com-
plications. Nevertheless, data are sparse and once again
the strength of that estimation is derived from the
Crimi et al. study [66], which explains the 84% of the
signal; hence, this estimate is very unstable. On the
other hand, there are 16 RCTs that evaluated selenium-
based strategies and when these results are statistically
aggregated, we observed a trend towards reduced mor-
tality (RR = 0.89, 95% CI 0.77 to 1.03, P = 0.12) and
infection (RR = 0.87, 95% CI 0.74 to 1.02, P = 0.08).
Nothwistanding, current knowledge shows that selenium
exhibits antioxidant, antiinflammatory and immunomo-
dulatory effects [73]. In this context, selenium has been
shown to inhibit the activation of nuclear factor kappa-
B (NF-kB) by controlling selenoprotein genes expression
[74,75]. Likewise, selenium suppresses C reactive protein
synthesis and increases release of L-selectin from mono-
cytes while decreasing soluble L-selectin, which has
been reported to be associated with high mortality in
septic patients [76]. These mechanisms are likely to con-
tribute to the modulatory effects of selenium on the
inflammatory response [75]. Therefore, we certainly
believe that selenium cannot be left out of antioxidant
treatment strategies in the critically ill.
We observed considerable variation in how selenium
is administered in the included RCTs and, thus, we con-
ducted several additional subgroup analyses to evaluate
whether we can optimize the treatment effect of sele-
nium-based strategies. We first compared studies that
Figure 7 Results of subgroup analyses examinating the effects of parenteral selenium supplementation on infections. RR, risk ratio. P-
values refer to the differences in the effects of selenium on infectious complications between subgroups.
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evaluated selenium as monotherapy and compared them
to studies of combination antioxidant therapy that
included selenium. We observed important trends
towards reduced mortality (RR = 0.86, 95% CI 0.73 to
1.01, P = 0.06) and reduced infectious complications
(RR = 0.85, 95% CI 0.71 to 1.03, P = 0.10) associated
with selenium monotherapy, and no evidence of a treat-
ment effect was associated with combination therapy.
These data support the notion that selenium could be
the cornerstone of antioxidant strategies [11]; however,
in this meta-analysis we have previously demonstrated
that non-selenium-based studies are also associated with
a significant positive treatment effect. Thus, we conclude
that a combination of selenium with other trace ele-
ments and vitamins is probably warranted.
Current knowledge from animal studies shows that
selenium given as an intravenous loading dose has a
biphasic action; initially as a pro-oxidant and then as an
antioxidant [77]. Nevertheless, the early transient pro-
oxidant effect of selenite might be a useful therapeutic
strategy for some ICU patients [78]. In early stages of
SIRS, a selenium loading dose given as an intravenous
bolus may be able to induce a direct reversible inhibi-
tion of NF-B binding to DNA, controlling gene expres-
sion and thus down-regulating the synthesis of pro-
inflammatory cytokines [76,79]]. Furthermore, in a
sheep model of severe sepsis, the bolus of sodium sele-
nite was able to improve hemodynamics, delaying arter-
ial hypotension, improving cardiac index, with delayed
hyperlactatemia, and fewer sepsis-induced microvascular
alterations [80]. Unfortunately, these findings have never
been proven in clinical trials. We explored the effect of
selenium loading dose as an intravenous bolus given in
a short time between 30 minutes and 2 hours. Accord-
ing to our results, a parenteral loading dose showed a
trend towards reduction in mortality (RR = 0.84, 95% CI
0.68 to 1.03, P = 0.09) whereas studies that did not use
a bolus loading dose did not show effect on mortality
(RR= 0.94, 95% CI 0.77 to 1.15, P = 0.56). The absence
of a significant test of subgroup differences weakens any
inferences from this subgroup analysis but it remains a
plausible hypothesis that studies that employ a bolus
loading dose may have a greater mortality effect than
those that did not.
In addition, we did not find any significant numerical
difference among different selenium daily doses. How-
ever, trials using daily doses greater than 500 μg showed
a trend towards a tendency to reduce mortality (P =
0.07). This finding is mostly due to the two German
RCTs [56,67], in which using a daily dose of 1,000 μg
showed a trend reduction in mortality.
The strength of our meta-analysis includes the fact
that we have used several methods to reduce bias (com-
prehensive literature search, duplicate data abstraction,
specific criteria for searching and analysis) and have
focused on clinically important primary outcomes. Not-
withstanding, we are aware that our meta-analysis has
several limitations. Perhaps, the major limitation was the
small number of trials included in certain subgroup ana-
lyses and the effect of one enteral, non-selenium RCT
[66] on the mortality in the parenteral vs. enteral sub-
groups analysis and the selenium vs. non selenium sub-
groups analysis. Moreover, in those RCTs that have
provided micronutrients as part of PN, such as SIGNET
[17], which supplemented PN selenium, a difference
between the prescribed and the provided dose is possi-
ble due to PN intolerance, which adds uncertainty about
the true selenium daily dose.
In spite of these limitations, we have demonstrated
that antioxidant supplementation in the critically ill may
significantly reduce overall mortality and shorten venti-
lation days with a trend towards reduction in infectious
complications. Nonetheless, many questions on antioxi-
dant strategies in the ICU still remain unanswered.
Further research is warranted to define the optimal
combination, optimal dose and the timing of supple-
mentation of micronutrients [9]. Although the optimal
time to start antioxidants could not be determined from
this meta-analysis, both experimental and clinical data
support the concept that antioxidants are more effective
when initiated prior to injury [3].
Conclusions
In this meta-analysis, we have demonstrated that trace
elements and vitamins as antioxidants may be able to
significantly decrease mortality and shorten mechanical
ventilation days and are associated with a trend towards
reduced infectious complications in critically ill patients.
The treatment effect may be greatest in patients with
greater severity of illness. Furthermore, the therapeutic
effect may also depend on the type of intervention and/
or the method of administration. Antioxidant cocktails
with intravenous selenium at high doses may optimize
the therapeutic effect of antioxidant strategies. Further
research to optimize the therapeutic effect of antioxi-
dants is warranted.
Key messages
• Critical illness is characterized by oxidative stress
with antioxidant depletion. In this context, supple-
mentation of antioxidant micronutrients could
restore antioxidant status, improving clinical
outcomes.
• Trace elements and vitamins, as antioxidants, may
significantly decrease mortality and shorten mechan-
ical ventilation days in ICU patients.
• Antioxidant micronutrients strategies are asso-
ciated with a trend towards a reduction in infections.
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• The treatment effect may be greatest in patients
with greater severity of illness.
• Antioxidant cocktails with intravenous selenium at
a daily dose higher than 500 μg may optimize the
therapeutic effect of antioxidant strategies.
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